• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Benlysta (belimumab)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Benlysta (belimumab)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Benlysta (belimumab) is a human IgG 1 À monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS). Elevated levels of BLyS are seen in the blood or joint fluid of patients with autoimmune and inflammatory disorders.

    Benlysta is specifically indicated for:

    • the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. Benlysta intravenous (IV) infusion is also indicated for use in pediatrics 5 years of age and older with systemic lupus erythematosus.
    • the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy.

    Benlysta may be administered as an intravenous infusion in patients aged 5 years and older or as a subcutaneous injection in patients aged 18 years and older.  The dosing recommendations are as follows:

    Intravenous Administration in Adults with SLE or Lupus Nephritis and Pediatric Patients with SLE −10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute, and administer as an intravenous infusion over a period of 1 hour. (2.1) −Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions.

    Subcutaneous Administration in Adults with SLE −200 mg once weekly.

    Subcutaneous Administration in Adults with LN - 400-mg dose (two 200-mg injections) once weekly for 4 doses, then 200 mg once weekly thereafter.

    Clinical Results

    The FDA approval of Benlysta was based on three randomized, double-blind, placebo-controlled studies involving 2,133 patients with SLE.
     

    Trial 1: Benlysta 1 mg/kg, 4 mg/kg, 10 mg/kg
    Trial 1 enrolled 449 subjects and evaluated doses of 1, 4, and 10 mg/kg Benlysta plus standard of care compared with placebo plus standard of care over 52 weeks. The co-primary endpoints were percent change in SELENA-SLEDAI score at Week 24 and time to first flare over 52 weeks. No significant differences between any of the Benlysta groups and the placebo group were observed. Exploratory analysis of this study identified a subgroup of subjects (72%), who were autoantibody positive, in whom Benlysta appeared to offer benefit. The results of this study informed the design of Trials 2 and 3 and led to the selection of a target population and indication that is limited to autoantibody-positive SLE patients.
     

    Trials 2 and 3: Benlysta 1 mg/kg and 10 mg/kg
    Trials 2 and 3 were randomized, double-blind, placebo-controlled trials in patients with SLE that were similar in design except - Trial 2 was 76 weeks duration and was conducted in North America and Europe.and Trial 3 was 52 weeks duration and was conducted in South America, Eastern Europe, Asia, and Australia. At screening, subjects were stratified by disease severity based on their SELENA-SLEDAI score, proteinuria level and race (African or Indigenous-American descent vs. other), and then randomly assigned to receive Benlysta 1 mg/kg, 10 mg/kg, or placebo in addition to standard of care. Treatment was administered intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days for 48 weeks in Trial 3 and for 72 weeks in Trial 2. The primary efficacy endpoint was a composite endpoint (SLE Responder Index or SRI) that defined response as meeting each of the following criteria at Week 52 compared with baseline:

    • ≥4-point reduction in the SELENA-SLEDAI score, and
    • no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores, and
    • no worsening (<0.30-point increase) in Physician’s Global Assessment (PGA) score

    In both Trials 2 and 3, the proportion of SLE patients achieving an SRI response, as defined for the primary endpoint, was significantly higher in the Benlysta 10 mg/kg group than in the placebo group. The trends in comparisons between the treatment groups for the rates of response for the individual components of the endpoint were generally consistent with that of the SRI. At Week 76 in Trial 2, the SRI response rate with Benlysta 10 mg/kg was not significantly different from that of placebo (39% and 32%, respectively).

    The efficacy of Benlysta IV for the treatment of SLE in pediatric patients was studied over 52 weeks in 93 pediatric patients with SLE. The proportion of pediatric patients achieving the composite primary endpoint, the SLE response index (SRI-4), was higher in pediatric patients receiving Benlysta IV plus standard therapy compared to placebo plus standard therapy. Pediatric patients who received Benlysta IV plus standard therapy also had a lower risk of experiencing a severe flare, as well as longer duration of time until a severe flare (160 days versus 82 days). The drug's safety and pharmacokinetic profiles in pediatric patients were consistent with those in adults with SLE.

    The FDA approval of Benlysta for use in adults with active lupus nephritis was based on BLISS-LN, a phase 3, 104-week, randomized, double-blind, placebo-controlled, post-approval commitment study. The study enrolled 448 patients who received intravenous (IV) Benlysta 10 mg/kg plus standard therapy (mycophenolate mofetil for induction and maintenance, or cyclophosphamide for induction followed by azathioprine for maintenance, plus steroids) or they received placebo plus standard therapy. The study met its primary endpoint demonstrating that a statistically significant greater number of patients achieved Primary Efficacy Renal Response (PERR) at two years (or 104 weeks) when treated with Benlysta plus standard therapy compared to placebo plus standard therapy (43% vs 32%).

    Side Effects

    Adverse effects associated with the use of Benlysta may include, but are not limited to, the following:

    • nausea
    • diarrhea
    • pyrexia
    • nasopharyngitis
    • bronchitis
    • insomnia
    • pain in extremity
    • depression
    • migraine
    • pharyngitis

    Mechanism of Action

    Benlysta (belimumab) is a human IgG 1 À monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BLyS). It blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. Benlysta does not bind B cells directly, but by binding BLyS, it inhibits the survival of B cells, including auto reactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

    Additional Information

    For additional information regarding Benlysta or systemic lupus erythematosus please visit the Benlysta web page.

    Approval Date: 2011-03-01
    Company Name: GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing